CD274 and cancer: mAbs acting as PD-1 inhibitors (as Nivolumab), PDL-1 inhibitors (as Atezolimumab), and CTLA-4 inhibitors (as Ipilimumab) are routinely administered, and it is estimated that around 20–40% of cancer patients benefit from this administration.